Episode

Bayer Acquires Perfuse in $2.45 Billion Deal

Podcast
Eyewire News: The Podcast
Published
May 6, 2026
Duration seconds
410
Processing state
not_requested
Canonical source
https://traffic.megaphone.fm/BMCL7214816195.mp3
Audio
https://traffic.megaphone.fm/BMCL7214816195.mp3
JSON
/v1/public/podcasts/eyewire-news-the-podcast-7055536/episodes/bayer-acquires-perfuse-in-2-45-billion-deal
Markdown
/podcast/eyewire-news-the-podcast-7055536/bayer-acquires-perfuse-in-2-45-billion-deal.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/eyewire-news-the-podcast-7055536/episodes/bayer-acquires-perfuse-in-2-45-billion-deal/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/eyewire-news-the-podcast-7055536/bayer-acquires-perfuse-in-2-45-billion-deal.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

Bayer expands ophthalmology pipeline with acquisiton of Perfuse Therapeutics; Viridian announces new phase 3 data for its investigational subcutaneous injection for chronic thyroid eye disease; and Steven Dell, MD discusses the impact of declining reimbursement could on ophthalmic practices. Learn more about your ad choices. Visit megaphone.fm/adchoices